Regen BioPharma Files Patent for mRNA Cancer Vaccine

Regen BioPharma has filed a provisional patent application covering utilization of dendritic cell technologies to augment efficacy of its patented survivin mRNA cancer immunotherapeutic vaccine. In 2021, the company was granted a patent on composition of matter of survivin modified-mRNA useful for teaching the immune system to kill cancer. That patent covered specific types of dendritic cells, means of generating specialized dendritic cells and the planned formulation that will enter clinical trials.

“We are proud of our collaborators and colleagues who have worked on our first issued survivin patent, which was filed in 2015, before the world realized the potency of modified-mRNA technology that was first successfully commercialized with the COVID-19 vaccines by Moderna and Pfizer,” said David Koos, PhD, DBA, CEO, and chairman of Regen BioPharma. “The currently filed application discloses means of significantly increasing efficacy by combining modified-mRNA with unique cellular immunotherapy, as well as adjuvant approaches. We chose this strategy to maximally protect our intellectual property around this potentially very valuable mRNA cancer immunotherapy vaccine.”

Immunotherapy of cancer represents a large market that is currently being led by the class of drugs called “checkpoint inhibitors” and “CAR-T” cells. To date, there is no mRNA immunotherapy available for treating cancer.